サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584095

糖ペプチド抗生物質市場：投与経路別、薬剤タイプ別、適応症別、エンドユーザー別、流通チャネル別、国別、地域別 -産業分析、市場規模、市場シェア、予測、2024年～2032年

Glycopeptide Antibiotics Market, By Route of Administration, By Drug Type, By Indication, By End User, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 322 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.28円
糖ペプチド抗生物質市場：投与経路別、薬剤タイプ別、適応症別、エンドユーザー別、流通チャネル別、国別、地域別 -産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年10月26日
発行: AnalystView Market Insights
ページ情報: 英文 322 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

糖ペプチド抗生物質の市場規模は2023年に32億4,073万米ドルとなり、2024年から2032年にかけてCAGR 7.20％で拡大

糖ペプチド抗生物質市場- 市場力学

がんと感染症の罹患率の増加が市場需要を促進

糖ペプチド系抗生物質は、ペプチドグリカンの産生を阻害することで細菌の細胞壁合成を阻害するため、βラクタム系抗生物質や他の抗生物質に耐性を持つ多剤耐性黄色ブドウ球菌（MRSA）や腸球菌感染症の治療に不可欠です。また、β-ラクタム系抗生物質にアレルギーのある患者の代替薬にもなります。糖ペプチド抗生物質の市場は、がんや感染症の罹患率の上昇に牽引され、今後数年間で大きく成長すると予想されています。例えば、米国疾病予防管理センター（CDC）は、2019年に175万2,735人の新規がん患者と59万9,589人のがん関連死亡者を報告しました。さらに、Globocan 2020のデータによると、英国では457,960人の新規がん患者と179,648人の死亡者が出ており、乳がん、前立腺がん、非ホジキンリンパ腫が最も多い悪性腫瘍となっています。このようながん罹患率の増加は、感染症を管理するための抗生物質の需要を増加させ、市場の成長を後押ししています。さらに、腸球菌感染症や結核などの感染症の流行が、糖ペプチド抗生物質の需要をさらに押し上げると予想されます。2022年9月のCDCデータによると、米国では2019年に8,916件の結核患者が記録されました。さらに、感染症治療のための新製品承認が市場拡大を後押ししています。例えば、2021年7月、AbbVie Inc.は、急性細菌性皮膚・皮膚構造感染症（ABSSSI）の治療に使用されるDALVANCEの米国FDA承認を取得し、糖ペプチド抗生物質市場の予想成長に貢献しています。

糖ペプチド抗生物質市場 - 主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024年～2032年）に約7.20％のCAGRで毎年成長すると推定されます。

薬剤タイプ別では、バンコマイシンが2023年に最大市場シェアを占めると予測

適応症のセグメンテーションに基づくと、2023年には皮膚および構造感染症が主要タイプでした。

地域別では、北米が2023年に収益を生み出す主要市場となっています。

糖ペプチド抗生物質市場 - セグメンテーション分析：

世界の糖ペプチド抗生物質市場は、投与経路、薬剤タイプ、適応症、エンドユーザー、流通チャネル、地域に基づいてセグメント化されます。

市場は薬剤タイプに基づいて4つのカテゴリーに分けられる：バンコマイシン、ダルババンバンシン、オリタバンバンシン、その他。糖ペプチド抗生物質市場では、バンコマイシンが長年にわたって臨床使用されており、重篤なグラム陽性感染症、特にメチシリン耐性黄色ブドウ球菌（MRSA）に対する有効性が実証されているため、依然として支配的な薬剤となっています。病院での広範な使用と、強力な安全性プロファイルおよび広範な臨床的エビデンスが、この薬剤のリーダーシップをより強固なものにしています。ダルババンサンシンやオリタバンサンシンなどの新しい代替薬は、投与間隔の延長などの利点があるもの、まだバンコマイシンの市場シェアには達していないです。その主な理由は、コストが高いことと、標準的な治療プロトコールにおいてバンコマイシンの優先順位が確立されていることです。

市場は適応症によってカテゴリーに分けられる：皮膚・構造感染、髄膜炎、クロストリジウム・ディフィシル感染、腸炎、その他です。適応症別では、皮膚・構造感染症が最大の市場シェアを占めており、これはヘルスケア環境での発生率の高さと抗生物質耐性菌の増加によるものです。このようなケースでは確実な治療が必要となるため、糖ペプチド抗生物質が不可欠となっています。クロストリジオイデス・ディフィシル感染症や髄膜炎などの他の疾患も重要であるが、皮膚感染症や構造感染症の流行と重要な性質が、糖ペプチド抗生物質市場における支配的な役割を確実なものにしています。

糖ペプチド抗生物質市場 - 地理的洞察

北米は糖ペプチド抗生物質市場において支配的な地域です。その主な理由は、高度なヘルスケアインフラ、抗生物質耐性感染症の高い流行、研究開発への多額の投資です。同地域の病院は、MRSAのような重篤なグラム陽性感染症を管理するために、これらの抗生物質、特にバンコマイシンを主に使用しています。さらに、規制の枠組みが整備され、感染対策が重視されていることも、糖ペプチド抗生物質の需要拡大に寄与しています。この地域には主要な製薬企業が存在し、臨床試験が進行中であるため、市場での優位性はさらに高まっています。

糖ペプチド抗生物質市場 - 競合情勢：

糖ペプチド抗生物質市場の各社は、競争力を強化し、製品の供給力を確保するために様々な戦略を採用しています。こうした取り組みの中心は研究開発であり、既存の製剤の改良と現在の抗生物質の新たな治療適応の開拓に重点を置いています。臨床試験のためのヘルスケア機関との協力は一般的で、これらの治療法の有効性と安全性を裏付ける重要なデータを生み出しています。規制当局の戦略には、新規または変更された治療法の承認プロセスを迅速化するために、ファストトラック指定を追求することも含まれます。さらに、ターゲットを絞ったマーケティングキャンペーンは、薬剤耐性感染症の管理において糖ペプチドが果たす重要な役割について医療従事者を教育することを目的としています。さらに、企業は戦略的な価格設定と償還交渉に取り組み、これらの必須抗生物質への幅広いアクセスを確保し、臨床現場での持続的な使用を促進しています。いくつかの提携や製品の上市が市場の成長に寄与しています。

目次

第1章 糖ペプチド抗生物質市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 糖ペプチド抗生物質の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 糖ペプチド抗生物質の産業調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 糖ペプチド抗生物質市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 糖ペプチド抗生物質市場情勢

  • 糖ペプチド抗生物質市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 糖ペプチド抗生物質市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 非経口
    • その他

第8章 糖ペプチド抗生物質市場- 薬剤タイプ別

  • 概要
    • 医薬品タイプ別セグメントシェア分析
    • バンコマイシン
    • ダルババンシン
    • オリタヴァンシン
    • その他

第9章 糖ペプチド抗生物質市場- 適応症別

  • 概要
    • セグメントシェア分析（適応症別）
    • 皮膚および構造の感染症
    • 髄膜炎
    • クロストリディオイデス・ディフィシル感染症
    • 腸炎
    • その他

第10章 糖ペプチド抗生物質市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • 専門クリニック
    • 在宅ケア
    • その他

第11章 糖ペプチド抗生物質市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他

第12章 糖ペプチド抗生物質市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- 糖ペプチド抗生物質業界

  • 競合ダッシュボード
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • NATCO Pharma Limited
    • Teva Pharmaceutical Industries Ltd
    • LUPIN Limited
    • Amneal pharmaceuticals LLC
    • Zydus Cadila
    • Sun Pharmaceutical Industries Ltd.
    • Alembic Pharmaceuticals Limited
    • Mylan NV
    • Hetero Group
    • Others

第14章 アナリストの全方位展望

目次
Product Code: ANV4085

REPORT HIGHLIGHT

Glycopeptide Antibiotics Market size was valued at USD 3,240.73 Million in 2023, expanding at a CAGR of 7.20% from 2024 to 2032.

Glycopeptide antibiotics, such as vancomycin and teicoplanin, are primarily used to treat severe Gram-positive bacterial infections. They function by inhibiting bacterial cell wall synthesis, which is essential for bacterial growth and structural integrity. Vancomycin is often used to manage infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile. These antibiotics are typically administered intravenously for systemic infections, while oral formulations are used to treat gastrointestinal infections. Due to their effectiveness against drug-resistant bacteria, glycopeptide antibiotics are crucial in hospital settings, particularly for managing complex infections and in surgical prophylaxis.

Glycopeptide Antibiotics Market- Market Dynamics

Increasing incidence of cancer and infectious diseases to propel market demand

Glycopeptide antibiotics inhibit bacterial cell wall synthesis by blocking peptidoglycan production, making them essential for treating multi-resistant Staphylococcus aureus (MRSA) and enterococcal infections that are resistant to beta-lactams and other antibiotics. They are also an alternative for patients allergic to beta-lactams. The market for glycopeptide antibiotics is expected to grow significantly in the coming years, driven by the rising incidence of cancer and infectious diseases. For example, the U.S. Centers for Disease Control and Prevention (CDC) reported 1,752,735 new cancer cases and 599,589 cancer-related deaths in 2019. Additionally, Globocan 2020 data showed 457,960 new cancer cases and 179,648 deaths in the U.K., with breast, prostate, and Non-Hodgkin's lymphoma being the most common malignancies. This rising cancer burden is increasing the demand for antibiotics to manage infections, boosting market growth. Moreover, the prevalence of infectious diseases, such as enterococcal infections and tuberculosis, is expected to further drive the demand for glycopeptide antibiotics. According to CDC data from September 2022, the U.S. recorded 8,916 tuberculosis cases in 2019. Additionally, new product approvals for treating infectious diseases are propelling market expansion. For instance, in July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, used in the treatment of acute bacterial skin and skin structure infections (ABSSSI), contributing to the anticipated growth of the glycopeptide antibiotic market.

Glycopeptide Antibiotics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2024-2032)

Based on Drug Type segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication segmentation, skin and structure Infection was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Glycopeptide Antibiotics Market- Segmentation Analysis:

The Global Glycopeptide Antibiotics Market is segmented on the basis of Route of Administration, Drug Type, Indication, End User, Distribution Channel, and Region.

The market is divided into four categories based on Drug Type: Vancomycin, Dalbavancin, Oritavancin, Others. In the glycopeptide antibiotics market, Vancomycin remains the dominant drug due to its long-standing clinical use and proven efficacy against serious Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). Its widespread use in hospitals, combined with a strong safety profile and extensive clinical evidence, reinforces its leadership. Although newer alternatives like Dalbavancin and Oritavancin offer benefits such as extended dosing intervals, they have not yet achieved Vancomycin's market share. This is primarily due to higher costs and the well-established preference for Vancomycin in standard treatment protocols.

The market is divided into two categories based on indication: Skin and Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis and Others. In the indication segment, skin and structure infections hold the largest market share, driven by their high occurrence in healthcare environments and the rising incidence of antibiotic-resistant bacteria. The need for reliable treatments in these cases has made glycopeptide antibiotics essential. While other conditions, such as Clostridioides difficile infections and meningitis, are also important, the prevalence and critical nature of skin and structure infections ensure their dominant role in the glycopeptide antibiotics market.

Glycopeptide Antibiotics Market- Geographical Insights

North America is the dominating region in the glycopeptide antibiotics market, primarily due to its advanced healthcare infrastructure, high prevalence of antibiotic-resistant infections, and significant investments in research and development. The region's hospitals are major consumers of these antibiotics, particularly Vancomycin, to manage serious Gram-positive infections like MRSA. Furthermore, supportive regulatory frameworks and a strong emphasis on infection control contribute to the growing demand for glycopeptide antibiotics. The presence of key pharmaceutical companies and ongoing clinical trials in this region further enhance its market leadership.

Glycopeptide Antibiotics Market- Competitive Landscape:

Companies in the glycopeptide antibiotics market adopt various strategies to enhance competitiveness and ensure product availability. Central to these efforts is research and development, with a focus on improving existing drug formulations and exploring new therapeutic indications for current antibiotics. Collaborations with healthcare institutions for clinical trials are common, generating critical data to support the efficacy and safety of these treatments. Regulatory strategies often include pursuing fast-track designations to expedite the approval process for new or modified treatments. Furthermore, targeted marketing campaigns aim to educate healthcare professionals about the critical role of glycopeptides in managing drug-resistant infections. In addition, companies engage in strategic pricing and reimbursement negotiations to ensure broader access to these essential antibiotics, facilitating their sustainable use in clinical practice. Several partnerships and product launches have contributed to the market's growth.

Recent Developments:

In July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, an antibiotic used to treat acute bacterial skin and skin structure infections in pediatric patients. Similarly, in July 2020, Sandoz International GmbH introduced a 500 mg Daptomycin injection in the U.S. market to treat complicated skin infections and certain bloodstream infections. These developments are boosting the market's expansion.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann-La Roche Ltd.
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • LUPIN Limited
  • Amneal pharmaceuticals LLC
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • Mylan N.V.
  • Hetero Group
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Vancomycin
  • Dalbavancin
  • Oritavancin
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Skin and Structure Infection
  • Meningitis
  • Clostridioides Difficile Infection
  • Enterocolitis
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospital
  • Specialty Clinics
  • Homecare
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Glycopeptide Antibiotics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Glycopeptide Antibiotics Market Snippet by Route of Administration
    • 2.1.2. Glycopeptide Antibiotics Market Snippet by Drug Type
    • 2.1.3. Glycopeptide Antibiotics Market Snippet by Indication
    • 2.1.4. Glycopeptide Antibiotics Market Snippet by End User
    • 2.1.5. Glycopeptide Antibiotics Market Snippet by Distribution Channel
    • 2.1.6. Glycopeptide Antibiotics Market Snippet by Country
    • 2.1.7. Glycopeptide Antibiotics Market Snippet by Region
  • 2.2. Competitive Insights

3. Glycopeptide Antibiotics Key Market Trends

  • 3.1. Glycopeptide Antibiotics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Glycopeptide Antibiotics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Glycopeptide Antibiotics Market Opportunities
  • 3.4. Glycopeptide Antibiotics Market Future Trends

4. Glycopeptide Antibiotics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Glycopeptide Antibiotics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Glycopeptide Antibiotics Market Landscape

  • 6.1. Glycopeptide Antibiotics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Glycopeptide Antibiotics Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 7.1.2. Oral
    • 7.1.3. Parenteral
    • 7.1.4. Others

8. Glycopeptide Antibiotics Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Vancomycin
    • 8.1.3. Dalbavancin
    • 8.1.4. Oritavancin
    • 8.1.5. Others

9. Glycopeptide Antibiotics Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Skin and Structure Infection
    • 9.1.3. Meningitis
    • 9.1.4. Clostridioides Difficile Infection
    • 9.1.5. Enterocolitis
    • 9.1.6. Others

10. Glycopeptide Antibiotics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospital
    • 10.1.3. Specialty Clinics
    • 10.1.4. Homecare
    • 10.1.5. Others

11. Glycopeptide Antibiotics Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Online pharmacies
    • 11.1.5. Others

12. Glycopeptide Antibiotics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Glycopeptide Antibiotics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Glycopeptide Antibiotics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Glycopeptide Antibiotics Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Glycopeptide Antibiotics Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Glycopeptide Antibiotics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Glycopeptide Antibiotics Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. F. Hoffmann-La Roche Ltd.
    • 13.2.2. NATCO Pharma Limited
    • 13.2.3. Teva Pharmaceutical Industries Ltd
    • 13.2.4. LUPIN Limited
    • 13.2.5. Amneal pharmaceuticals LLC
    • 13.2.6. Zydus Cadila
    • 13.2.7. Sun Pharmaceutical Industries Ltd.
    • 13.2.8. Alembic Pharmaceuticals Limited
    • 13.2.9. Mylan N.V.
    • 13.2.10. Hetero Group
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us